Change of focus for Sumitomo after ulotaront trial setback

18 March 2024
research_biotech_microscopes_lab_big

Japanese drugmaker Sumitomo Pharma (TYO: 4506) and its US subsidiary Sumitomo Pharma America have amended a  collaboration with Otsuka Pharmaceuticals (TYO: 4578).

Agreed in late 2021, the deal has seen the firms jointly develop and commercialize four compounds in neuropsychiatry, including ulotaront (SEP-363856) and SEP-4199.

At the time, Otsuka agreed to pay $270 million upfront, with Sumitomo’s US division, then known as Sunovion, also being eligible for milestone payments of up to $620 million.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical